Trastuzumab-modified DM1-loaded nanoparticles for HER2+ breast cancer treatment: an in vitro and in vivo study
Authors: Xinkuang Liu
Xueke Liu
Ling Rong
Shuping Zhou
Tao Jing
Xiaolong Tang
Yinci Zhang
Shiyu Cai
Amin Li
Journal: Artificial Cells Nanomedicine and Biotechnology (2017)
Discipline: BIOLOGY & BIOCHEMISTRY
Keywords: Emtansine (DM1); HER2+ tumors; drug delivery; targeting nanoparticles.
Affiliations: Bozhou People’s Hospital Affiliated to Medical College, Anhui University of Science &amp; Technology, Bozhou, China;, Medical College, Anhui University of Science &amp; Technology, Huainan, China;, Huainan First People’s Hospital and First Affiliated Hospital of Medical College, Anhui University of Science &amp; Technology, Huainan, China

Abstract:  Background: Emtansine (DM1) is a highly potent anti-microtubule agent that has shown promising results for breast cancer treatment, but side effects limit its widespread clinical use. In this research, a new nano-drug was developed to integrate DM1 agent with antibody targeting. Methods: A system of novel nanoparticles (NPs) DM1-NPs-trastuzumab (DM1-NPs-Tmab) of DM1 combined with (anti-HER2 antibody, Herceptin®, Trastuzumab) was developed for HER2+ breast cancer treatment, and its physical characterization and antitumor biological activity were investigated. Results: DM1-NPs-Tmab-targeted HER2+ breast cancer cells specifically were developed. Compared with naked DM1 and Herceptin, DM1-NPs-Tmab showed greater toxicity on HER2+ cancer cells and blocked the HER2-PI3K/Akt cell activation pathway. DM1-NPs-Tmab inhibited tumor growth by 88% and had less toxic effects in vivo than non-targeting DM1 when administered to MDA-MB-453 xenograft bearing mice. Conclusion: DM1-NPs-Tmab shows superior anti-tumor efficacy than free Herceptin or DM1. DM1-NPs-Tmab is a potential promising formulation for targeting biotherapy of HER2+ tumors. 

Retracted: Yes

PubPeer comments:
 In Figure 7b, images of two tumors have been duplicated and presented as something else. In Figure 5c, the flowcytometry dot plots show red and gray data points. Can the authors explain the difference between red and gray? ![file] , 
 #1 This is a serious problem of nature. Due to our lack of strict control lead to such unreal pictures appeared. We immediately applied to the magazine to retract the manuscript, and apologized for the serious negative effection caused by this, and thank you very much for your supervision and support! , 
 Retracted [11 January 2021] . ------------------------------------------------- We, the authors, Editors and Publisher of the journal Artificial Cells, Nanomedicine, and Biotechnology, have retracted the following article: Ling Rong, Shuping Zhou, Xinkuang Liu, Amin Li, Tao Jing, Xueke Liu, Yinci Zhang, Shiyu Cai Xiaolong Tang (2018) Trastuzumab-modified DM1-loaded nanoparticles for HER2+ breast cancer treatment: an in vitro and in vivo study. Artificial Cells, Nanomedicine, and Biotechnology, 46:8, 1708u20131718, DOI: 10.1080 21691401.2017.1391821 Since publication, the authors noticed errors in Figures 7u2009b and 5c, which directly impacts the reported results and conclusions. The authors alerted the issue to the Editor and Publisher and all have agreed to retract the article to ensure correction of the scholarly record. The authors plan to re-run the experiment and verify their data. We have been informed in our decision-making by our policy on publishing ethics and integrity and the COPE guidelines on retractions. The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as u2018Retractedu2019. ,